Skip to content
Cultural Foundation
Author:
Oculis Holding AG
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
June 11, 2026
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
June 9, 2026
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
June 8, 2026
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 29, 2026
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
May 14, 2026
Oculis Reports Q1 2026 Financial Results and Provides Company Update
May 11, 2026
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
May 7, 2026
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 5, 2026
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 1, 2026
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
1
2
Next Page
→